Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
VDR 7421 DIHYDROTACHYSTEROL CHEMBL2106324 agonist, antagonist TdgClinicalTrial, TEND, DrugBank, TTD 20525913, 17139284, 17016423, 8380156, 11752352, 1336906
VDR 7421 LITHOCHOLIC ACID CHEMBL1478 agonist GuideToPharmacologyInteractions
VDR 7421 TACALCITOL CHEMBL2105611 agonist GuideToPharmacologyInteractions
VDR 7421 PEFCALCITOL CHEMBL3137307 agonist ChemblInteractions
VDR 7421 TESTOSTERONE CHEMBL386630 NCI 12796696
VDR 7421 CALCIFEDIOL CHEMBL3544909 agonist ChemblInteractions
VDR 7421 ERGOCALCIFEROL CHEMBL1536 agonist, antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 20525913, 17207992, 17440943, 18290715, 11752352, 20091647, 16949927, 17519354, 17218095
VDR 7421 LEXACALCITOL CHEMBL432600 agonist GuideToPharmacologyInteractions, DrugBank 17139284, 17016423
VDR 7421 CHEMBL551326 CHEMBL551326 TdgClinicalTrial, DrugBank
VDR 7421 CAFFEINE CHEMBL113 NCI 11684540
VDR 7421 VALSPODAR CHEMBL1086218 NCI 10609555
VDR 7421 RETINOL CHEMBL986 NCI 10609868, 9627692
VDR 7421 DP001 CHEMBL605525 agonist GuideToPharmacologyInteractions, ChemblInteractions
VDR 7421 CLINDAMYCIN CHEMBL1753 agonist GuideToPharmacologyInteractions
VDR 7421 FALECALCITRIOL CHEMBL2106158 TdgClinicalTrial
VDR 7421 CYCLOSPORINE CHEMBL160 NCI 10609555
VDR 7421 CHOLECALCIFEROL CHEMBL1042 agonist, binder ChemblInteractions, DrugBank, TTD 11752352, 20435140, 15503649
VDR 7421 ALFACALCIDOL CHEMBL1601669 agonist DrugBank 11752352, 20435140, 15503649
VDR 7421 INECALCITOL CHEMBL2105107 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 10592235
VDR 7421 BECOCALCIDIOL CHEMBL2104955 agonist ChemblInteractions, DrugBank 10592235
VDR 7421 CALCIPOTRIOL CHEMBL1234231 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
VDR 7421 ESTRONE SODIUM SULFATE CHEMBL2106240 PharmGKB
VDR 7421 MEDROXYPROGESTERONE ACETATE CHEMBL717 PharmGKB
VDR 7421 ILX23-7553 CHEMBL284121 agonist ChemblInteractions
VDR 7421 CALCITRIOL CHEMBL846 agonist, antagonist PharmGKB, DrugBank, NCI, GuideToPharmacologyInteractions, TEND, TdgClinicalTrial, ChemblInteractions, TTD 11752352, 15503649, 11158396
VDR 7421 PARICALCITOL CHEMBL1200622 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 17139284, 17016423, 19494617, 11752352, 20204178, 16076355
VDR 7421 SEOCALCITOL CHEMBL1908376 agonist GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 17139284, 17016423
VDR 7421 LUNACALCIPOL CHEMBL2105705 agonist ChemblInteractions, DrugBank
VDR 7421 CAMPTOTHECIN CHEMBL65 NCI 7510956
VDR 7421 HYDROCORTISONE CHEMBL389621 NCI 14705237, 1647304
VDR 7421 KETOCONAZOLE CHEMBL295698 NCI 2546501
VDR 7421 CHEMBL410893 CHEMBL410893 agonist GuideToPharmacologyInteractions
VDR 7421 LG-190178 CHEMBL197589 agonist GuideToPharmacologyInteractions
VDR 7421 CALCIPOTRIENE CHEMBL1200666 agonist TdgClinicalTrial, ChemblInteractions
VDR 7421 CLODRONATE DISODIUM CHEMBL1520188 PharmGKB
VDR 7421 CALCIUM CHEMBL2146121 PharmGKB
VDR 7421 Elocalcitol CHEMBL3545094 agonist TdgClinicalTrial, ChemblInteractions
VDR 7421 MEDRONIC ACID CHEMBL180570 PharmGKB
VDR 7421 DOXERCALCIFEROL CHEMBL1200810 agonist, antagonist, suppressor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank, TTD 21169421
VDR 7421 TAMOXIFEN CHEMBL83 NCI 8388708, 1315250
VDR 7421 STANOLONE CHEMBL27769 NCI 12532336
VDR 7421 STAUROSPORINE CHEMBL388978 NCI 7588324
VDR 7421 VITAMIN K CHEMBL1201519 NCI 1336373
VDR 7421 ESTRADIOL CHEMBL135 NCI 1315250
VDR 7421 CYTARABINE CHEMBL803 NCI 1849032
VDR 7421 CHEMBL35482 CHEMBL35482 NCI 15930183
VDR 7421 ALENDRONIC ACID CHEMBL870 PharmGKB, NCI 12608943
VDR 7421 BICALUTAMIDE CHEMBL409 NCI 15754350

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
VDR rs7975232 AA deferasirox metabolism/PK yes In regression analyses, ApaI AA (P=0.007; ß=-0.626; 95% CI: - 234.300 to - 61.833) AUC parameters results were statistically significant different from AC + CC. Genotype AA is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to genotypes AC + CC. 29099735 1449004990
VDR rs2228570 G deferasirox metabolism/PK yes In regression analyses, FokI CC (P = 0.008; ß = 0.645; 95% CI: 62.993–258.94) AUC parameters results were statistically significant different from CT +TT. Furthermore, FokI SNP, TT/TC (N = 7) group had median t1/2 of 8.429 h (IQR: 6.05–92.62 h) and CC (N = 7) had 4.879 h (IQR: 4.68–5.70 h). FokI TC/CC (P = 0.003; ß = - 0.604; 95% CI: - 57.526 to - 20.660), with BMI (P = 0.027; ß = 0.380; 95% CI: 0.551–5.553) and AST levels (P = 0.010; ß = - 0.464; 95% CI: -57.526 to -20.660), was retained in linear regression model. In regression analysis, FokI CC (P=0.010; ß=0.544; 95% CI: 5.498–26.571) results for maximum serum concentration were statistically significant. Allele G is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to allele A. 29099735 1449004998
VDR rs2239179 C selective beta-2-adrenoreceptor agonists efficacy yes Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele T. 15282200 827690019
VDR rs1540339 C selective beta-2-adrenoreceptor agonists efficacy yes Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele T. 15282200 827690011
VDR rs731236 G zoledronate efficacy no as measured by bone mineral density response at the lumbar spine, femoral neck, and hip. Allele G is not associated with response to zoledronate in people with beta-Thalassemia. 18443790 827822925
VDR rs7975232 C zoledronate efficacy no as measured by bone mineral density response at the lumbar spine, femoral neck, and hip. Allele C is not associated with response to zoledronate in people with beta-Thalassemia. 18443790 827822943
VDR rs1544410 T zoledronate efficacy no as measured by bone mineral density response at the lumbar spine, femoral neck, and hip. Allele T is not associated with response to zoledronate in people with beta-Thalassemia. 18443790 827822903
VDR rs11574077 TT irinotecan metabolism/PK yes The pharmacokinetic analysis focused on markers that, even if not presenting a significant effect in the replication cohort (p > 0.05), presented a concordant effect on the toxicity risk in both cohorts (same size effect according to the same genetic model). The association of these polymorphisms with the pharmacokinetic parameters was investigated in a subset of 71 patients from the discovery cohort, and the most relevant results (p < 0.1; concordant genetic model) . Genotype TT is associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype CT. 29706892 1449557344
VDR rs11568820 CT + TT midazolam metabolism/PK yes Genotypes CT + TT are associated with increased clearance of midazolam as compared to genotype CC. 22484315 981565062
VDR rs12717991 T irinotecan metabolism/PK no Allele T is not associated with metabolism of irinotecan in people with Colorectal Neoplasms as compared to allele C. 29706892 1449557376
VDR rs1544410 C midazolam metabolism/PK yes CC > CT > TT. Allele C is associated with increased clearance of midazolam as compared to allele T. 22484315 981505272
VDR rs4516035 T midazolam metabolism/PK yes TT > TC > CC. Allele T is associated with increased clearance of midazolam as compared to allele C. 22484315 981505339
VDR rs1544410 TT rifampin metabolism/PK yes (alleles complemented) Genotype TT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotypes CC + CT. 28594304 1448632196
VDR rs11568820 TT daclatasvir metabolism/PK yes Complemented to plus strand. Genotype TT is associated with decreased concentrations of daclatasvir in people with Hepatitis C as compared to genotypes CC + CT. 29790402 1449564095
VDR rs11168292 GG warfarin dosage yes This SNP is in very tight linkage disequilibrium with rs11168293 and rs4760658 (r2>0.97). Mean dose (in mg) of warfarin according to genotype was: GG>CG>CC. p-value adjusted for CYP2C9 metabolizer status and VKORC1 activity status phenotypes, among other factors. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation. Genotype GG is associated with increased dose of warfarin as compared to genotypes CC + CG. 29298995 1449164032
VDR rs11168293 TT warfarin dosage yes This SNP is in very tight linkage disequilibrium with rs11168292 and rs4760658 (r2>0.97). Mean dose (in mg) of warfarin according to genotype was: TT>GT>GG. p-value adjusted for CYP2C9 metabolizer status and VKORC1 activity status phenotypes, among other factors. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation. Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT. 29298995 1449164037
VDR rs4760658 GG warfarin dosage yes This SNP is in very tight linkage disequilibrium with rs11168293 and rs11168292 (r2>0.97). Mean dose (in mg) of warfarin according to genotype was: GG>AG>AA. p-value adjusted for CYP2C9 metabolizer status and VKORC1 activity status phenotypes, among other factors. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation. Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG. 29298995 1449164026
VDR rs1544410 TT deferasirox efficacy yes Patients with the TT genotype had lower liver stiffness values (proxy measurement for liver fibrosis) as compared to patients with the CC or CT genotypes. However, there was no association between this variant and liver T2* values. Please note that alleles have been complemented to the positive strand. Genotype TT is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT. 30651574 1450932822
VDR rs731236 GG deferasirox efficacy yes Patients with the GG genotype had lower liver stiffness values (proxy measurement for liver fibrosis) as compared to patients with the AA or AG genotypes. However, there was no association between this variant and liver T2* values. Please note that alleles have been complemented to the positive strand. Genotype GG is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes AA + AG. 30651574 1450932816
VDR rs2228570 A peginterferon alfa-2b efficacy yes This genotype is associated with sustained virological response (SVR). Allele A is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G. 24073221 1444706633
VDR rs2228570 AA warfarin dosage no This variant alone is not significantly associated with warfarin dose. However, "patients with the genotype combination GT,TT/CT,CC of VDR rs7975232/rs2228570 required significantly higher stable warfarin dose (5.79±2.02mg) than those with the other genotypic combinations (5.19±1.78mg, p=0.034). Multivariate analysis showed that VDR rs7975232/rs2228570 explained 2.0% of the 47.5% variability in overall warfarin dose." Genotype AA is not associated with decreased dose of warfarin as compared to genotypes AG + GG. 28262345 1449005229
VDR rs7975232 CC warfarin dosage no This variant alone is not significantly associated with warfarin dose. However, "patients with the genotype combination GT,TT/CT,CC of VDR rs7975232/rs2228570 required significantly higher stable warfarin dose (5.79±2.02mg) than those with the other genotypic combinations (5.19±1.78mg, p=0.034). Multivariate analysis showed that VDR rs7975232/rs2228570 explained 2.0% of the 47.5% variability in overall warfarin dose." Genotype CC is not associated with decreased dose of warfarin as compared to genotypes AA + AC. 28262345 1449005223